Calls

Source: S&P Capital IQ transcripts via Xpressfeed · latest indexed call 2026-05-07 · generated 2026-07-20.

Latest call digest

Zoetis Inc., Q1 2026 Earnings Call, May 07, 2026 · 2026-05-07T12:30:00

Q1 2026 (reported May 7, 2026) was the sharpest negative inflection in this call history. Management opened by conceding the quarter "unfolded differently than expected, particularly in companion animal." Organic operational revenue was flat and adjusted net income grew 1%, but the gap between the prepared remarks and the Q&A reality was wide: a fiscal-year-alignment change shifted roughly $100 million of international sales from Q4 2025 into the quarter, and excluding it revenue would have declined about 5%.

Beneath the headline, U.S. revenue fell 8% and U.S. companion animal fell 11%, with key dermatology down 11% and Librela down 13%. Management tied this to a convergence of vet-clinic price increases and lower traffic, pet-owner price sensitivity, and intensified competition that — unlike prior cycles — did not expand the market. International (+10%) and livestock (+12%) again cushioned the result.

The actually-stated guidance was cut: full-year organic operational revenue to 2%–5% (from the 3%–5% set in February) and adjusted net income to 2%–6%. Management launched a comprehensive cost and productivity program, lowered its aggregate price assumption to 1%–2%, and announced an agreement to acquire Neogen's animal genomics business. The Q&A was dominated by doubt that a roughly flat Q1 can bridge to the full-year guide, and by whether the market itself has structurally weakened.

Participant coverage from the latest call.

Group	Participants	Count
Management	Operator; Steven Frank — Vice President of Investor Relations, Zoetis Inc.; Kristin Peck — CEO & Director, Zoetis Inc.; Wetteny Joseph — Executive VP & CFO, Zoetis Inc.	4
Analysts	Michael Ryskin — MD & Research Analyst, BofA Securities, Research Division; Erin Wilson Wright — Equity Analyst, Morgan Stanley, Research Division; Brandon Vazquez — Analyst, William Blair & Company L.L.C., Research Division; Christopher Schott — Senior Analyst, JPMorgan Chase & Co, Research Division; Jonathan Block — MD & Senior Equity Research Analyst, Stifel, Nicolaus & Company, Incorporated, Research Division; Steven Dechert — Associate, KeyBanc Capital Markets Inc., Research Division; Navann Ty Dietschi — Pharmaceuticals and Medtech Analyst, BNP Paribas, Research Division; Daniel Christopher Clark — Research Analyst, Leerink Partners LLC, Research Division; Andrea Zayco Narvaez Alfonso — Healthcare Analyst, UBS Investment Bank, Research Division; Christopher LoBianco — Research Associate, TD Cowen, Research Division	10

Curated latest-call exchanges; one row per analyst topic.

Analyst	Firm	Topic	What changed in Q&A
Michael Ryskin	BofA Securities	Near-term levers vs. multi-year competition; the guidance bridge	Pushed that the biggest pipeline launches are years out and competition is still early, then asked management to reconcile a roughly flat Q1 with the full-year guide, calling the implied ramp aggressive. Management pointed to share stabilization in paras and Librela and easier second-half comps.
Erin Wright	Morgan Stanley	Implied companion-animal ramp, channel destock, script denials	Probed whether the guide bakes in a distributor/retail restock. Management said it is not assuming inventory returns and is operating at the low end of a post-2023 range.
Brandon Vazquez	William Blair	Whether animal health has structurally become less durable	Framed price sensitivity, no market expansion and generics as a 'new world.' Peck rejected that reading, citing the human-animal bond, urgent-care and diagnostics strength, and no expected generics in key categories.
Christopher Schott	JPMorgan	Pricing reaction to competitor promotions; U.S. companion trajectory	Management said it will not lead on price, will use selective actions and promotions, and expects key franchises to grow low-to-mid single digits — a step down from the initial guide.
Jonathan Block	Stifel	Quantifying the channel hit; whether Zoetis is pivoting to a cheaper option	Asked to size the U.S. Pet Health channel impact; management did not quantify it and attributed it to soft demand. Peck clarified list prices are not being cut — the focus is point-of-sale affordability and loyalty programs.
Navann Ty Dietschi	BNP Paribas	Pricing strategy in derm and for upcoming renal/oncology/cardiology launches	Management set aggregate price expectation at 1%–2% (down from 2%–3%) and said a competitor raised JAK prices, narrowing but not closing the gap to Zoetis.
Andrea Zayco Narvaez Alfonso	UBS	Gross-margin trajectory and whether Neogen is in the guide	Q1 gross margin was 71.8% (up ~140 bps ex-FX); management said the 2%–5% range could accommodate a Neogen close in the second half.

Theme tracker

Themes are curator-classified across supplied calls.

Theme	Status	Quarters mentioned	Read-through
U.S. clinic softness and pet-owner price sensitivity	persisted	Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026	Began as overall-visit softness that management said was offset by therapeutic strength and alternative channels. By Q3 2025 through Q1 2026 therapeutic visits themselves fell and multi-year vet-clinic price increases were cited as the cause, making this the primary drag rather than a manageable headwind.
Key dermatology competition (oral JAK/IL-31 entrants)	persisted	Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026	For over a year framed as manageable via first-mover advantage and market expansion, with only 'limited' share loss. In Q1 2026 key derm fell 11% as price sensitivity and competition combined without market growth to cushion the effect.
Librela / OA pain recovery	persisted	Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026	From a fast 2024 blockbuster launch to 2025 declines blamed on social-media/safety perception, met with a multi-pronged education and Phase IV strategy. By Q1 2026 U.S. Librela rose sequentially for the first time in six quarters, with long-acting Lenivia launching in the EU and Canada.
Livestock as the diversification ballast	persisted	Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026	Consistent above-market growth (a third consecutive year in 2025, then 12% in Q1 2026) that repeatedly offset companion-animal weakness, aided by the MFA divestiture and rising protein demand.
Alternative and retail channel growth	persisted	Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026	Retail and home delivery grew roughly 25%–30% through 2024–2025 and cushioned clinic softness, but slowed to about 10% in Q1 2026 partly on retail script denials — removing a key offset just as clinic demand weakened.
Fiscal-year alignment / accounting recast	emerged	Q4 2025, Q1 2026	Introduced in Q4 2025, the calendar alignment shifted about $100 million of international sales into Q1 2026 and complicated comparability. Management said it was expected to add 200–250 bps to full-year 2026 growth, but the weak environment more than offset that.
Tariff exposure	dropped	Q1 2025, Q2 2025	A central topic in early 2025 (with a stated ~$20 million net headwind embedded and extensive Section 232 lobbying) that has since faded from active discussion, superseded by macro, competition and the fiscal-year-alignment mechanics.

Guidance ledger

Quotes, calls, and speakers are source-verified; outcomes are curator-classified.

Verbatim guidance	Call	Speaker	Curator outcome	Outcome note
“Looking ahead to 2026, we are guiding to a range of 3% to 5% organic operational revenue growth and expect 3% to 6% organic operational growth in adjusted net income.”	Zoetis Inc., Q4 2025 Earnings Call, Feb 12, 2026 · 2026-02-12T13:30:00	Kristin Peck	missed	One quarter later, on the Q1 2026 call, the floor of both ranges was cut, to 2%–5% revenue and 2%–6% adjusted net income.
“we would return to our normal rate range, which is 2% to 3%, which is what you can assume in this guidance”	Zoetis Inc., Q4 2025 Earnings Call, Feb 12, 2026 · 2026-02-12T13:30:00	Wetteny Joseph	missed	By Q1 2026 the aggregate price expectation had been lowered to a 1% to 2% range, per management on that call.
“We are revising our full year revenue guidance to a range of $9.4 billion and $9.475 billion and organic operational growth of 5.5% to 6.5% based on a more measured view of macro and operational trends in the back half of the year.”	Zoetis Inc., Q3 2025 Earnings Call, Nov 04, 2025 · 2025-11-04T13:30:00	Wetteny Joseph	kept	Full-year 2025 landed at 6% organic operational revenue growth per the Q4 2025 call, within this range.
“we are raising our full year guidance for organic operational revenue growth to 6.5% to 8%.”	Zoetis Inc., Q2 2025 Earnings Call, Aug 05, 2025 · 2025-08-05T12:30:00	Kristin Peck	missed	This raised range was cut to 5.5%–6.5% the next quarter, and full-year 2025 finished at 6%, below the 6.5% floor set here.
“We are maintaining our full year organic operational revenue guidance range of 6% to 8%”	Zoetis Inc., Q1 2025 Earnings Call, May 06, 2025 · 2025-05-06T12:30:00	Kristin Peck	kept	Full-year 2025 delivered 6% organic operational revenue growth, at the low end of this range.

Q&A pressure map

Question counts and firms are curator tallies; analyst coverage shown above.

Topic	Questions	Firms	Pressure / response
Credibility of the full-year ramp after a flat Q1	3	BofA Securities, Morgan Stanley, JPMorgan	Analysts repeatedly asked management to bridge a roughly flat Q1 to the 2%–5% full-year guide, questioning the implied second-half acceleration. Management leaned on easier back-half comps, franchise stabilization and cost actions rather than a demand rebound.
Pricing strategy amid competitor promotions	4	JPMorgan, Stifel, KeyBanc, BNP Paribas	Several analysts pressed whether Zoetis would cut list price or defend on promotions. Management held that it will not lead on price and disclosed its aggregate price assumption had dropped to 1%–2%.
Competitive intensity in dermatology and parasiticides	3	BofA Securities, William Blair, BNP Paribas	Questions focused on whether new entrants are lasting rather than launch-phase, and whether competition is now on efficacy as well as price. Management said promotions are lasting longer than historically but still expects them to stabilize.
Distributor and retail destocking / script denials	2	Morgan Stanley, Stifel	Analysts asked management to isolate and quantify the channel headwind on U.S. companion animal. Management said the channel had normalized but did not provide the specific dollar impact requested, attributing the effect back to soft end-market demand.

Language shifts

Only language evidence verified against the referenced component is shown.

Observation	Verbatim evidence	Call ID	Component
Management opened the latest call by conceding the quarter missed plan — a departure from prior confident openings that led with strong broad-based growth.	“the quarter unfolded differently than expected, particularly in companion animal”	1993042978	2
The CFO stated results were below plan outright, language not used in the prior several quarters.	“performance that is below our expectations this quarter”	1993042978	3
A new cost-discipline vocabulary entered the narrative, signaling a shift from an investment-led posture to defensive cost action.	“launched a comprehensive cost and productivity program”	1993042978	2
For contrast, three quarters earlier the tone emphasized broad-based strength, underscoring how far the register shifted by Q1 2026.	“we delivered strong broad-based 8% organic operational revenue growth”	1951458863	2

The call history traces a clean inflection: three years of resilient, above-market growth giving way through 2025 and into Q1 2026 to slowing companion-animal demand, price-driven competition and a string of guidance cuts. The open question for investors is whether this is cyclical pressure that stabilizes, as management argues, or a more durable reset to bridge before the 2027–2028 pipeline arrives.